Table 5.

The Frequency of the NQO1 Polymorphism in 56 t-AML Patients According to Their Primary Cytotoxic Treatment

No. of Patients5-150No. of Patients With
Wild-Type AllelesHeterozygous Mutation Homozygous Mutation
Observed Expected Observed ExpectedObserved Expected
Alkylating agents  43  21  26.23 17  14.62  5  2.06  
Topo II inhibitors  27  13 16.47  11  9.18  3  1.30  
Anti-metabolites  17 7  10.37  9  5.78  1  0.82  
Anti-tubulin drugs 30  15  18.30  12  10.20  3  1.44 
Radiotherapy  37  18  22.57  16  12.58  3 1.78  
Totals  56  27  34.42  23  18.93  6 2.66 
No. of Patients5-150No. of Patients With
Wild-Type AllelesHeterozygous Mutation Homozygous Mutation
Observed Expected Observed ExpectedObserved Expected
Alkylating agents  43  21  26.23 17  14.62  5  2.06  
Topo II inhibitors  27  13 16.47  11  9.18  3  1.30  
Anti-metabolites  17 7  10.37  9  5.78  1  0.82  
Anti-tubulin drugs 30  15  18.30  12  10.20  3  1.44 
Radiotherapy  37  18  22.57  16  12.58  3 1.78  
Totals  56  27  34.42  23  18.93  6 2.66 
F5-150

Patients are listed more than once if they received more than one class of drugs or radiotherapy.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal